TP-5809

TP-5809 is an investigational **small-molecule** targeted anticancer agent being developed by Sumitomo Pharma Oncology and originated through collaboration with researchers at Brigham Young University. It is a potent **tyrosine kinase non-receptor 1 inhibitor** designed to block aberrant TNK1 signaling, with reported low-nanomolar biochemical activity and cellular target engagement. Preclinical studies indicate that TP-5809 suppresses TNK1-dependent downstream signaling, including STAT3 and STAT5 phosphorylation, and inhibits tumor growth in xenograft models, supporting development in **hematologic malignancies** such as **Hodgkin lymphoma** and other TNK1-driven cancers. Publicly available information indicates that the program remained in the **preclinical** stage and had been described as ready for human clinical testing after completion of required preclinical safety and toxicology work.